查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867597

溶瘤病毒療法：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Oncolytic Virus Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 77 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球溶瘤病毒療法市場預計在 2024 年達到 1.06 億美元，預計到 2031 年將達到 2.13 億美元，2025 年至 2031 年的複合年成長率為 10.4%。

溶瘤病毒療法是一種創新的癌症治療方法，它利用基因工程改造的病毒選擇性地感染並摧毀癌細胞，同時激活宿主免疫系統，引發全身性抗腫瘤反應。這些病毒能夠直接溶解腫瘤細胞並刺激免疫抗原性細胞死亡，使其成為免疫腫瘤學領域的重要治療方法方向。與化療和放射線治療不同，溶瘤病毒治療方法具有更高的腫瘤選擇性、更低的毒性，並且與免疫查核點抑制劑聯合使用時，具有強大的協同效應。例如，talimogene laherparepvec (T-VEC) 等產品已獲得美國食品藥物管理局 (FDA) 的核准，並在治療黑色素瘤方面展現出良好的療效，引起了全球製藥公司的廣泛研發和商業關注。

隨著免疫腫瘤學和精準醫療的進步，溶瘤病毒療法正經歷快速發展。透過諸如美國FDA的突破性療法認定和歐盟的PRIME計畫等舉措，世界各地的監管機構都在推動創新，並支持加速臨床試驗和早期商業化。癌症，尤其是進行性固態腫瘤發生率的不斷上升，凸顯了對新型作用機制的迫切需求。此外，大型生物製藥公司正積極投資於該領域的併購和策略合作，大幅擴展其研發管線。自2023年以來，已有多個溶瘤病毒候選藥物進入III期臨床試驗，顯示該領域正朝著工業化規模應用的方向穩步邁進。

儘管前景可期，但溶瘤病毒療法的研發仍面臨許多重大挑戰。高效的體內遞送和腫瘤特異性標靶化仍是技術難題，尤其是在免疫抑制微環境或病毒清除迅速的患者身上。臨床試驗耗費大量資源，需要漫長的週期、巨額資金以及病毒學、免疫學和轉化醫學等跨學科合作。安全性問題依然存在，包括脫靶感染和全身性發炎的風險。此外，該行業缺乏廣泛的商業性成功案例，導致投資者情緒謹慎，投資回報也存在不確定性。

下游對創新癌症治療方法的需求正在迅速成長，溶瘤病毒被認為是下一代免疫療法聯合療法的關鍵組成部分。初步數據顯示，溶瘤病毒與PD-1/PD-L1阻斷等查核點抑制劑合併使用，可能提高包括膠質母細胞瘤、胰臟癌和膀胱癌在內的難治性腫瘤的療效。這引起了臨床醫生和患者群體的廣泛關注。此外，亞太地區正在崛起為重要的成長引擎，中國、日本和韓國等國家的支持性政策和不斷增加的臨床試驗活動，為未來的區域商業化策略奠定了基礎。

本報告旨在按地區/國家、類型和應用對全球溶瘤病毒療法市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

溶瘤病毒療法市場規模、估計值和預測均以銷售收入為指標，以 2024 年為基準年，並包含 2020 年至 2031 年的歷史數據和預測數據。透過定量和定性分析，讀者可以製定業務和成長策略，評估競爭格局，分析自身在當前市場中的地位，並就溶瘤病毒療法做出明智的商業決策。

市場區隔

公司

  • Amgen
  • RIGVIR Group
  • 3s-guojian
  • Shuanghe Pharmaceutical

按類型分類的細分市場

  • 基於HSV的溶瘤病毒
  • 基於腺病毒的溶瘤病毒
  • 基於痘苗病毒的溶瘤病毒
  • 基於水痘口炎病毒的溶瘤病毒
  • 基於新城疫病毒的溶瘤病毒

應用領域

  • 黑色素瘤
  • 攝護腺癌
  • 乳癌
  • 卵巢癌
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Oncolytic Virus Therapy was estimated to be worth US$ 106 million in 2024 and is forecast to a readjusted size of US$ 213 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.

Oncolytic Virus Therapy is an innovative cancer treatment approach that employs genetically modified viruses to selectively infect and destroy tumor cells while activating the host's immune system to launch a systemic anti-tumor response. These viruses induce direct oncolysis and stimulate immunogenic cell death, positioning them as a pivotal class in immuno-oncology. Unlike chemotherapy or radiotherapy, this modality offers enhanced tumor selectivity, reduced toxicity, and strong synergistic potential when combined with immune checkpoint inhibitors. Products like Talimogene laherparepvec (T-VEC) have received FDA approval, showing promising efficacy in melanoma and drawing increasing R&D and commercial attention from global pharmaceutical companies.

With breakthroughs in immuno-oncology and the advancement of precision medicine, oncolytic virus therapy is entering a period of rapid growth. Global regulatory bodies are encouraging innovation through frameworks like the FDA's Breakthrough Therapy designation and the EU's PRIME program, facilitating clinical acceleration and early commercialization. The increasing incidence of cancer, particularly advanced solid tumors, underscores the unmet demand for novel mechanisms of action. Furthermore, leading biopharmaceutical companies are actively investing in M&A and strategic partnerships in this space, significantly expanding their pipelines. Since 2023, several oncolytic virus candidates have advanced into Phase III trials, marking a clear shift toward industrial scalability.

Despite promising prospects, several key challenges persist in the development of oncolytic virus therapies. Efficient in vivo delivery and tumor-specific targeting remain technical hurdles, especially in patients with immunosuppressive microenvironments or rapid viral clearance. Clinical trials are resource-intensive, requiring long timelines, significant funding, and multidisciplinary collaboration spanning virology, immunology, and translational medicine. Safety concerns also linger, including risks of off-target infection and systemic inflammation. Additionally, the industry still lacks a broad base of commercially successful precedents, leading to cautious investment sentiment and uncertain return on investment timelines.

The downstream demand for innovative cancer therapies is rapidly rising, with oncolytic viruses increasingly recognized as critical components of next-generation immunotherapy combinations. In difficult-to-treat tumors such as glioblastoma, pancreatic cancer, and bladder cancer, preliminary data indicates enhanced efficacy when combined with checkpoint inhibitors like PD-1/PD-L1. Clinical practitioners and patient communities alike are showing growing interest. Moreover, the Asia-Pacific region is emerging as a significant growth engine, with supportive policies and increasing clinical trial activity in countries like China, Japan, and South Korea, paving the way for future regional commercialization strategies.

This report aims to provide a comprehensive presentation of the global market for Oncolytic Virus Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oncolytic Virus Therapy by region & country, by Type, and by Application.

The Oncolytic Virus Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Virus Therapy.

Market Segmentation

By Company

  • Amgen
  • RIGVIR Group
  • 3s-guojian
  • Shuanghe Pharmaceutical

Segment by Type

  • HSV-based Oncolytic Viruses
  • Adenoviruses-based Oncolytic Viruses
  • Vaccinia Virus-based Oncolytic Viruses
  • Vesicular Stomatitis Virus-based Oncolytic Viruses
  • Newcastle Disease Virus-based Oncolytic Viruses

Segment by Application

  • Melanoma
  • Prostate Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Oncolytic Virus Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Oncolytic Virus Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Oncolytic Virus Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Oncolytic Virus Therapy Product Introduction
  • 1.2 Global Oncolytic Virus Therapy Market Size Forecast (2020-2031)
  • 1.3 Oncolytic Virus Therapy Market Trends & Drivers
    • 1.3.1 Oncolytic Virus Therapy Industry Trends
    • 1.3.2 Oncolytic Virus Therapy Market Drivers & Opportunity
    • 1.3.3 Oncolytic Virus Therapy Market Challenges
    • 1.3.4 Oncolytic Virus Therapy Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Oncolytic Virus Therapy Players Revenue Ranking (2024)
  • 2.2 Global Oncolytic Virus Therapy Revenue by Company (2020-2025)
  • 2.3 Key Companies Oncolytic Virus Therapy Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Oncolytic Virus Therapy Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Oncolytic Virus Therapy
  • 2.6 Oncolytic Virus Therapy Market Competitive Analysis
    • 2.6.1 Oncolytic Virus Therapy Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Oncolytic Virus Therapy Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Therapy as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 HSV-based Oncolytic Viruses
    • 3.1.2 Adenoviruses-based Oncolytic Viruses
    • 3.1.3 Vaccinia Virus-based Oncolytic Viruses
    • 3.1.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
    • 3.1.5 Newcastle Disease Virus-based Oncolytic Viruses
  • 3.2 Global Oncolytic Virus Therapy Sales Value by Type
    • 3.2.1 Global Oncolytic Virus Therapy Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Oncolytic Virus Therapy Sales Value, by Type (2020-2031)
    • 3.2.3 Global Oncolytic Virus Therapy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Melanoma
    • 4.1.2 Prostate Cancer
    • 4.1.3 Breast Cancer
    • 4.1.4 Ovarian Cancer
    • 4.1.5 Others
  • 4.2 Global Oncolytic Virus Therapy Sales Value by Application
    • 4.2.1 Global Oncolytic Virus Therapy Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Oncolytic Virus Therapy Sales Value, by Application (2020-2031)
    • 4.2.3 Global Oncolytic Virus Therapy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Oncolytic Virus Therapy Sales Value by Region
    • 5.1.1 Global Oncolytic Virus Therapy Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Oncolytic Virus Therapy Sales Value by Region (2020-2025)
    • 5.1.3 Global Oncolytic Virus Therapy Sales Value by Region (2026-2031)
    • 5.1.4 Global Oncolytic Virus Therapy Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Oncolytic Virus Therapy Sales Value, 2020-2031
    • 5.2.2 North America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Oncolytic Virus Therapy Sales Value, 2020-2031
    • 5.3.2 Europe Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Oncolytic Virus Therapy Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Oncolytic Virus Therapy Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Oncolytic Virus Therapy Sales Value, 2020-2031
    • 5.5.2 South America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Oncolytic Virus Therapy Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Oncolytic Virus Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Oncolytic Virus Therapy Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.3.2 United States Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.4.2 Europe Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.5.2 China Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.6.2 Japan Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.7.2 South Korea Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Oncolytic Virus Therapy Sales Value, 2020-2031
    • 6.9.2 India Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Amgen
    • 7.1.1 Amgen Profile
    • 7.1.2 Amgen Main Business
    • 7.1.3 Amgen Oncolytic Virus Therapy Products, Services and Solutions
    • 7.1.4 Amgen Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Amgen Recent Developments
  • 7.2 RIGVIR Group
    • 7.2.1 RIGVIR Group Profile
    • 7.2.2 RIGVIR Group Main Business
    • 7.2.3 RIGVIR Group Oncolytic Virus Therapy Products, Services and Solutions
    • 7.2.4 RIGVIR Group Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
    • 7.2.5 RIGVIR Group Recent Developments
  • 7.3 3s-guojian
    • 7.3.1 3s-guojian Profile
    • 7.3.2 3s-guojian Main Business
    • 7.3.3 3s-guojian Oncolytic Virus Therapy Products, Services and Solutions
    • 7.3.4 3s-guojian Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
    • 7.3.5 3s-guojian Recent Developments
  • 7.4 Shuanghe Pharmaceutical
    • 7.4.1 Shuanghe Pharmaceutical Profile
    • 7.4.2 Shuanghe Pharmaceutical Main Business
    • 7.4.3 Shuanghe Pharmaceutical Oncolytic Virus Therapy Products, Services and Solutions
    • 7.4.4 Shuanghe Pharmaceutical Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Shuanghe Pharmaceutical Recent Developments

8 Industry Chain Analysis

  • 8.1 Oncolytic Virus Therapy Industrial Chain
  • 8.2 Oncolytic Virus Therapy Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Oncolytic Virus Therapy Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Oncolytic Virus Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Oncolytic Virus Therapy Market Trends
  • Table 2. Oncolytic Virus Therapy Market Drivers & Opportunity
  • Table 3. Oncolytic Virus Therapy Market Challenges
  • Table 4. Oncolytic Virus Therapy Market Restraints
  • Table 5. Global Oncolytic Virus Therapy Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Oncolytic Virus Therapy Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Oncolytic Virus Therapy Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Oncolytic Virus Therapy Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Oncolytic Virus Therapy
  • Table 10. Global Oncolytic Virus Therapy Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Therapy as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Oncolytic Virus Therapy Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Oncolytic Virus Therapy Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Oncolytic Virus Therapy Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Oncolytic Virus Therapy Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Oncolytic Virus Therapy Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Oncolytic Virus Therapy Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Oncolytic Virus Therapy Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Oncolytic Virus Therapy Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Oncolytic Virus Therapy Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Oncolytic Virus Therapy Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Oncolytic Virus Therapy Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Oncolytic Virus Therapy Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Oncolytic Virus Therapy Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Oncolytic Virus Therapy Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Oncolytic Virus Therapy Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Oncolytic Virus Therapy Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Oncolytic Virus Therapy Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Oncolytic Virus Therapy Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Amgen Basic Information List
  • Table 32. Amgen Description and Business Overview
  • Table 33. Amgen Oncolytic Virus Therapy Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Amgen (2020-2025)
  • Table 35. Amgen Recent Developments
  • Table 36. RIGVIR Group Basic Information List
  • Table 37. RIGVIR Group Description and Business Overview
  • Table 38. RIGVIR Group Oncolytic Virus Therapy Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Oncolytic Virus Therapy Business of RIGVIR Group (2020-2025)
  • Table 40. RIGVIR Group Recent Developments
  • Table 41. 3s-guojian Basic Information List
  • Table 42. 3s-guojian Description and Business Overview
  • Table 43. 3s-guojian Oncolytic Virus Therapy Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Oncolytic Virus Therapy Business of 3s-guojian (2020-2025)
  • Table 45. 3s-guojian Recent Developments
  • Table 46. Shuanghe Pharmaceutical Basic Information List
  • Table 47. Shuanghe Pharmaceutical Description and Business Overview
  • Table 48. Shuanghe Pharmaceutical Oncolytic Virus Therapy Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Shuanghe Pharmaceutical (2020-2025)
  • Table 50. Shuanghe Pharmaceutical Recent Developments
  • Table 51. Key Raw Materials Lists
  • Table 52. Raw Materials Key Suppliers Lists
  • Table 53. Oncolytic Virus Therapy Downstream Customers
  • Table 54. Oncolytic Virus Therapy Distributors List
  • Table 55. Research Programs/Design for This Report
  • Table 56. Key Data Information from Secondary Sources
  • Table 57. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Oncolytic Virus Therapy Product Picture
  • Figure 2. Global Oncolytic Virus Therapy Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Oncolytic Virus Therapy Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Oncolytic Virus Therapy Report Years Considered
  • Figure 5. Global Oncolytic Virus Therapy Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Oncolytic Virus Therapy Revenue in 2024
  • Figure 7. Oncolytic Virus Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. HSV-based Oncolytic Viruses Picture
  • Figure 9. Adenoviruses-based Oncolytic Viruses Picture
  • Figure 10. Vaccinia Virus-based Oncolytic Viruses Picture
  • Figure 11. Vesicular Stomatitis Virus-based Oncolytic Viruses Picture
  • Figure 12. Newcastle Disease Virus-based Oncolytic Viruses Picture
  • Figure 13. Global Oncolytic Virus Therapy Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Oncolytic Virus Therapy Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Product Picture of Melanoma
  • Figure 16. Product Picture of Prostate Cancer
  • Figure 17. Product Picture of Breast Cancer
  • Figure 18. Product Picture of Ovarian Cancer
  • Figure 19. Product Picture of Others
  • Figure 20. Global Oncolytic Virus Therapy Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 21. Global Oncolytic Virus Therapy Sales Value Market Share by Application, 2024 & 2031
  • Figure 22. North America Oncolytic Virus Therapy Sales Value (2020-2031) & (US$ Million)
  • Figure 23. North America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Europe Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Europe Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Asia Pacific Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Asia Pacific Oncolytic Virus Therapy Sales Value by Region (%), 2024 VS 2031
  • Figure 28. South America Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. South America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Middle East & Africa Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Middle East & Africa Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 32. Key Countries/Regions Oncolytic Virus Therapy Sales Value (%), (2020-2031)
  • Figure 33. United States Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. United States Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 35. United States Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 36. Europe Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Europe Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Europe Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 39. China Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. China Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 41. China Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Japan Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Japan Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Japan Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 45. South Korea Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. South Korea Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 47. South Korea Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Southeast Asia Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. Southeast Asia Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 50. Southeast Asia Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 51. India Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. India Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 53. India Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 54. Oncolytic Virus Therapy Industrial Chain
  • Figure 55. Oncolytic Virus Therapy Manufacturing Cost Structure
  • Figure 56. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 57. Bottom-up and Top-down Approaches for This Report
  • Figure 58. Data Triangulation
  • Figure 59. Key Executives Interviewed